Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMT-101-A01
- Development stage
- Preclinical
- Lead developer
- IMMUSE
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
IMT-101-A01 is a preclinical **antibody-drug conjugate** being developed by IMMUSE for **solid cancer**. It is described by the company as an ADC candidate derived from the IMT-101 new chemical entity program and built with IMMUSE's novel payload-linker technology, with the intended goal of delivering cytotoxic or immunomodulatory payload activity to **tumor cells and immune cells within the tumor microenvironment** to modulate antitumor immunity. IMMUSE's broader platform focus is on therapies addressing the tumor microenvironment and exhausted or dysfunctional T cells in solid tumors, but the specific molecular target, antibody specificity, payload identity, and linker composition for IMT-101-A01 have not been publicly disclosed.
- Other names
- IMT-101-A01-IMMUSE-ADC-Solid CancerIMT101-A01-IMMUSE-ADC-Solid CancerIMT 101-A01-IMMUSE-ADC-Solid Cancer
Beyond the preview
Go deeper on IMT-101-A01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMT-101-A01.